Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454739 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A
A Phase 3 study, sponsored by Bioverativ Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT01454739 is a Phase 3 study that has completed, run by Bioverativ Therapeutics. The registered enrollment target is 240 participants.
The verdict
NCT01454739, a Phase 3 study, has completed, sponsored by Bioverativ Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the long-term safety of recombinant human Factor VIII Fc fusion protein (rFVIIIFc) in participants with hemophilia A. The secondary objective of the study is to evaluate the efficacy of rFVIIIFc in the prevention and treatment of bleeding episodes in participants with hemophilia A.
Interventions
- DRUG rFVIIIFc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2011-12 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454739
The ClinicalTrials.gov registry entry for NCT01454739 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rFVIIIFc is the first listed.
NCT01454739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01454739 about?
NCT01454739 is a clinical study titled "Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A". The primary objective of the study is to evaluate the long-term safety of recombinant human Factor VIII Fc fusion protein (rFVIIIFc) in participants with hemophilia A. The secondary objective of the study is to evaluate the efficacy of rFVIIIFc in the prevention and treatment of bleeding episodes in...
What is the current status of trial NCT01454739?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2011-12. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01454739?
The interventions under investigation include: rFVIIIFc (DRUG).
Who is sponsoring clinical trial NCT01454739?
This trial is sponsored by Bioverativ Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.